The Serological Reactions in a Case of Rift Valley Fever

L. N. BinnDepartment of Hazardous Operations, Walter Reed Army Institute of Research, Department of Medicine, School of Medicine, University of Maryland, Washington 12, D. C.

Search for other papers by L. N. Binn in
Current site
Google Scholar
PubMed
Close
,
Raymond RandallDepartment of Hazardous Operations, Walter Reed Army Institute of Research, Department of Medicine, School of Medicine, University of Maryland, Washington 12, D. C.

Search for other papers by Raymond Randall in
Current site
Google Scholar
PubMed
Close
,
V. R. HarrisonDepartment of Hazardous Operations, Walter Reed Army Institute of Research, Department of Medicine, School of Medicine, University of Maryland, Washington 12, D. C.

Search for other papers by V. R. Harrison in
Current site
Google Scholar
PubMed
Close
,
C. J. Gibbs Jr.Department of Hazardous Operations, Walter Reed Army Institute of Research, Department of Medicine, School of Medicine, University of Maryland, Washington 12, D. C.

Search for other papers by C. J. Gibbs Jr. in
Current site
Google Scholar
PubMed
Close
, and
C. G. AulisioDepartment of Hazardous Operations, Walter Reed Army Institute of Research, Department of Medicine, School of Medicine, University of Maryland, Washington 12, D. C.

Search for other papers by C. G. Aulisio in
Current site
Google Scholar
PubMed
Close
Restricted access

Summary

The neutralizing (N), hemagglutination-inhibition (HI), and complement-fixation (CF) antibody responses following a laboratory infection with Rift Valley fever (RVF) virus in an individual have been determined. Neutralizing, HI, and CF antibodies persisted for the 18-month period of observation for which the individual was available. The advantages in economy and time required to perform HI and CF tests over the N test would be of particular value where serological cross-reactions do not occur, for example RVF.

Following inoculation of 2 cynomolgus monkeys with 106 mouse LD50 of pantropic RVF virus, the persistence of N, HI, and CF antibodies was observed for a 4-month period.

Author Notes

Present address: National Institutes of Health, Public Health Service, Department of Health, Education and Welfare, Bethesda, Maryland.

Save